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SUMMARY
Anti-endothelial cell antibodies (AECA) have been detected in 51 lupus sera by cell surface
radioimmunoassay with a prevalence of 39-2% for IgG and 45 1% for IgM-AECA. No correlations
were found between AECA and different clinical or laboratory parameters, including the presence of
anti-cardiolipin antibodies and signs associated with the presence of anti-phospholipid antibodies.
However, absorption with cardiolipin liposomes partially inhibited endothelial cell binding, and
affinity purified anti-cardiolipin antibodies were able to react with intact human endothelial cells. The
binding did not occur via Fc receptors since blocking ofFc receptors with rabbit IgG did not affect the
endothelial cell reactivity. Taken together our findings support the hypothesis that antibodies
directed against negatively charged phospholipids can be part of the anti-endothelial cell antibodies
in certain lupus sera. The possible role of these cross-reacting antibodies in the pathogenesis of
vascular thrombosis in lupus patients is discussed.
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INTRODUCTION
Anti-endothelial cell antibodies (AECA) have been demon-
strated in sera from patients affected by systemic lupus erythe-
matosus (SLE) and their presence has been related to vascular
injury (Cines et al., 1984; Le Roux et al., 1986; Hashemi,
Douglas-Smith & Izaguirre, 1987).
In addition a significant association between IgGAECA and
lupus-like anticoagulant (LLAC) has been shown recently in a
small series ofSLE patients (Le Roux et al., 1986). Carreras and
Vermylen (1982) first showed that immunoglobulin fractions
from sera of patients with LLAC activity inhibited prostacyclin
release from endothelial cells, suggesting a possible interference
of anti-phospholipid antibodies and endothelial cells (Carreras
et al., 1981; Carreras & Vermylen, 1982). However, further
studies reported conflicting results (Izaguirre et al., 1987; Rustin
et al., 1987; Petraiuolo, Bovill & Hoak, 1987; Hasselaar et al.,
1987).
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It is from this standpoint that we proceeded to investigate
the possible relationship between AECA and other anti-
phospholipid antibodies associated with LLAC, namely the
anti-cardiolipin antibodies (Harris et al., 1983). For this pur-
pose we studied 51 SLE sera for their binding activity to
cardiolipin and endothelial cells using both whole sera and
affinity purified anti-cardiolipin fractions.
Our results indicate that anti-endothelial cell antibodies are
a heterogenous population which may contain subsets of
antibodies cross-reacting with cardiolipin and phospholipid
structures present on the surface of intact human endothelial
cells.
MATERIALS AND METHODS
Patients
We studied 51 sera from SLE patients, who satisfied the revised
American Rheumatism Association classification for SLE (Tan
et al., 1982). The following information was recorded for all
patients: age, sex, duration of the disease, prednisone and
cytotoxic therapy, organ involvement (cutaneous, musculoske-
letal, hematologic, renal, neurologic, serositis and Raynaud
phenomenon), current or past clinical events reported to be
associated with anti-phospholipid antibodies and laboratory
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data (anti-nuclear and anti-dsDNA antibodies, complement,
lupus-like anti-coagulant, venereal disease reference laboratory
test).
Endothelial cell culture
Endothelial cells were harvested from human umbilical cord
veins by collagenase digestion using established methods (Jaffe
et al., 1973). Endothelial cells were grown onto 0-1% gelatine
coated tissue culture flasks (Costar, Cambridge, MA.), in
medium El 99 (Flow Labs., Irvine, Scotland, UK) supplemented
with 20% heat-inactivated newborn calf serum (NCS, Gibco,
Grand Island, NY), 100 U/ml penicillin, 100 yg/ml streptomy-
cin (Eurobio, Paris, France) and 1% L-glutamine (Flow Labs.,
Irvine, Scotland, UK). Endothelial cell growth factor (50 pg/ml)
prepared according to the method of Maciag et al. (1979) and
heparin (90 Mg/ml) were also added to cultures. Cells were fed
every three days, and, when confluent, subcultured by exposure
to 0 05% trypsin-0-02% EDTA (trypsin-EDTA, Flow Labs.,
Irvine, Scotland, UK). These cells met morphological criteria
for endothelial cells and were positive for Factor VIII antigen
(Jaffe, Hoyer & Nachman, 1973).
Anti-endothelial cell antibody assay
Anti-endothelial cell antibodies were detected using a solid-
phase radioimmunoassay with modifications of the method of
Cines et al. (1984). Primary cultures of endothelial cells from at
least two donors were detached by exposure to trypsin-EDTA
and placed onto gelatin-coated 96-well microtitre plates (Cos-
tar, Cambridge, MA.) at a concentration of 2 x 104 cells/well in
complete medium. Cells reached a confluent monolayer in about
24 h. Plates were washed twice with Hank's Balanced Salt
Solution (HBSS, Flow Labs., Irvine, Scotland, UK) 200 p1/well.
Free protein binding sites were then blocked by adding 200 p1/
well of blocking buffer (HBSS-l % Bovine Serum Albumin,
Sigma Chemicals Co., St. Louis, Mo.) and incubated for 1 h at
room temperature. After two washes with HBSS, 100 p1 of the
test serum (diluted 1/25 with HBSS) or 100 p1 of affinity purified
anti-cardiolipin antibodies (diluted with HBSS at a concentra-
tion of 250 pg/ml) were added to each well in triplicate. Plates
were incubated for 2 h at room temperature and then washed
three times with HBSS. One hundred microlitres of '25I-labelled
affinity purified goat anti-human IgG or IgM (diluted with
HBSS at a concentration of 5 pg/ml) were added to each well
and incubated for 2 h at room temperature. Four washes were
then performed with HBSS (200 p1/well) and 100 p1 of lysis
buffer (0-1% SDS-0-025 M NaOH) were added to each well.
Solubilized endothelial cells were collected using Q-tip swabs
and associated radioactivity was measured in a gamma-counter.
The amount (ng) bound of anti-human IgG or IgM of the
positive control sera at the standard dilution of 1/25 was
arbitrarily chosen as 100% endothelial cell binding activity.
Positive control sera were run on each plate and test sample
binding activity was expressed as percentage of positive refer-
ence sera. This was accomplished by the following formula: (ng
bound of sample/ng bound of reference serum) x 100. Thus, the
conversion of bound values to a percentage of endothelial cell
binding activity ofthe reference sera eliminated the between day
variation and ensured accuracy in comparison of results. Values
greater than three standard deviations above the mean of 16
normal subjects were considered raised, namely 33 30% for
IgG-AECA and 33-28% for IgM-AECA. In absorption experi-
ments and in experiments carried out with affinity purified
fractions, the values were expressed as ng bound of the anti-IgG
or anti-IgM antisera.
The following controls were included in each plate as
references: a sample from a pool of 16 healthy subjects (negative
sample), a positive (IgG or IgM) AECA reference serum,
blocking buffer (blank) and Cohn Fraction II (Sigma Chemicals
Co., St. Louis, Mo.) or normal human IgM (Behring Inst., Italy)
diluted with HBSS at the concentration of 250 pg/ml when
affinity purified preparations were tested.
The endothelial cells remained attached and confluent
during every passage of the assay, without any significant
morphological change as documented by examination under
phase contrast light microscopy and Giemsa staining.
Anti-phospholipid antibodies
Anti-cardiolipin antibodies (ACA) were detected using a solid-
phase radioimmunoassay as previously described (Tincani et al.,
1985; Meroni et al., 1987). The test was performed according to
recommendations of the recent workshop on standardization of
the anti-cardiolipin antibody test (Harris et al., 1987). Results
were expressed as ng bound of '251I-labelled affinity purified anti-
human IgG or IgM. Values higher than three standard devia-
tions above the mean of 40 normal sera were considered raised,
namely 3 55 ng for IgG-ACA and 7 40 ng for IgM-ACA.
Anti-phosphatidylserine antibodies (APSA) were measured
by a solid phase radioimmunoassay. Briefly, phosphatidylserine
(Sigma Chemicals Co., St. Louis, Mo.; 25 p1, 50 pg/ml in
methanol: chloroform 4: 1) was coated on polystyrene micro-
titre wells (Indywell, Greiner, Germany) by evaporation under
nitrogen as previously described (Harris et al., 1985). The plates
were blocked for 2 h and washed three times with 10% Fetal Calf
Serum (FCS; Flow Labs., Irvine, Scotland, UK) in phosphate-
buffered saline (PBS). The sera diluted 1/50 in FCS-PBS were
added to plates and incubated for 4 h at room temperature.
After three washes with FCS-PBS, affinity purified '251-labelled
goat antibodies against human IgG or IgM were added. The
plates were incubated overnight, washed three times and then
the wells were counted.
Absorption experiments
Absorption experiments were performed as previously de-
scribed (Meroni et al., 1987). Briefly, the sera were mixed with
cardiolipin liposomes, incubated for 1 h at 37°C and overnight
at 4°C. The mixtures were then centrifuged at 30,000 g for 15
min at 4°C and the supernatants kept as absorbed sera.
The results of inhibition studies were expressed as percent-
age inhibition of anti-cardiolipin, anti-phosphatidylserine and
anti-endothelial cells antibody binding activity. Percentage
inhibition was calculated as follows:
% inhibition=
(1 - ct/min after cardiolipin absorption-background
ct/min before cardiolipin absorption - background)
x 100
Affinity purified anti-cardiolipin antibodies
Affinity purified ACA were prepared from patients' sera using
cardiolipin liposomes as previously described (Meroni et al.,
1987; Harris et al., 1985).
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Lupus like anticoagulant (LLAC) (a)
LLAC was detected as previously described (Tincani et al.,
1985).
Antibodies to double stranded DNA (ds-DNA) 0o
Anti-dsDNA were detected by the Farr assay using '4C ds-DNA -
(Amersham International) as previously described (Tincani et
al., 1985). Results were given in percentage of antigen bound.
The upper limit of normal (mean+3 s.d.) was 25%.
0
v 5
Venereal disease reference laboratory test '
The venereal disease laboratory reference test was performed by
commercial slide flocculation test (Wellcome Foundation
Limited, UK).
Statistical analysis
Statistical analysis was performed by chi-square tests with 1/10Serum dilu
Yates' correction.
RESULTS
Anti-endothelial cell antibodies
Serial titration experiments were performed to determine the
serum dilution that provided optimal experimental conditions.
The 1/25 dilution, which displayed the highest binding activity
in the reference serum and the lowest background values in
normal sera, was selected (Fig. 1).
There was negligible binding of affinity purified '251-labelled
goat anti-human IgG or IgM to endothelial cells or to gelatin
coated plates. Experiments were also carried out with cells fixed
by 0.0625% paraformaldehyde for 10 min at 220C, as described
by Cines et al. (1984). Six positive and six negative sera did not
display significant variations in binding activity on fixed and
unfixed endothelial cells (data not shown). However, to exclude
any possible alterations in the endothelial cell surfaces, the
assays were performed without paraformaldehyde fixation.
Fifty-one SLE sera were tested for anti-endothelial cell anti-
bodies (AECA); 20 were positive for IgG-AECA (39 2%) and 23
for IgM-AECA (45-1%); eight were positive for both isotypes
(15.6%).
We were unable to find significant correlations between
AECA and any clinical or laboratory parameters investigated
and in particular with signs and symptoms reported to be
associated with anti-phospholipid antibodies, such as venous or
arterial thrombosis, fetal loss and thrombocytopenia. In con-
trast the positivity of IgG-ACA was significantly associated
with history of thrombosis (P < 0 05), fetal loss (P< 0-01) and
the presence of LLAC (P< 0 05).
Prevalence ofanti-endothelial cell antibodies in ACA positive and
ACA negative SLE sera
Figure 2 shows the distribution of IgG and IgM AECA in ACA
positive and ACA negative SLE patients. Positivities for anti-
endothelial cells were present either in anti-cardiolipin positive
or negative sera and no correlation was found between the two
antibodies.
Absorption experiments with cardiolipin liposomes
In order to assess whether anti-cardiolipin antibodies can be
responsible, at least in part, for the endothelial cell binding, 18
sera positive both for ACA and AECA were tested for anti-
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Fig. 1. Titration experiments with a reference serum positive for IgG
anti-endothelial cell antibodies (Fig. la) and for IgM anti-endothelial
cells antibodies (Fig. lb). The control was a pool from 16 normal sera.
The endothelial cell reactivity is expressed as ng ofanti-IgG or anti-IgM
bound. (0 O) IgG positive serum, (A A) Normal human serum,
(0- ) IgM positive serum.
endothelial cell activity after absorption with cardiolipin lipo-
some suspensions. As shown in Table 1, using high concentra-
tions of cardiolipin liposomes (12 mg/ml) we completely
inhibited the anti-phospholipid activity detected either as anti-
cardiolipin or anti-phosphatidylserine binding activity. In con-
trast, all the sera retained their activity against unfixed endothe-
lial cells. However, partial inhibition, ranging from 10-1 to
50 1%, was found in seven out of 18 ACA and AECA positive
SLE sera (Table 1).
The specificity of the absorption test was supported by the
fact that antibody activities directed against different antigens,
namely anti-nuclear or anti-mitochondrial type M2 antibodies,
were not affected by the absorption procedures, as previously
reported (Meroni et al., 1987).
A. Vismara et al.
IgG -AECA
10^
-
C)
01
._
c
,a)
a)
10
0
0
0
0
0
0
0
0
0
00*
IgM-AECA
0
0
0
0
0
0
0 0
0 0
* 0
**00
000 0*
* 0
- 00 0906
: *0
*0
IgG ACA (+) IgG ACA (-)
0
0
0
0
0 0
0
0
0 0
IgM ACA (+)
0
0
0
0
0 0
0 0
0 0
0
0 0
0.01
0
IgM ACA (-)
100
50
10
Fig. 2. Prevalence of IgG or IgM anti-endothelial cell antibodies (AECA) in ACA positive or negative SLE sera. The horizontal line
represents the mean values + 3 s.d. of percentage binding activity to endothelial cells of 16 normal sera (see Materials & Methods).
Table 1. Percentage inhibition of anti-cardiolipin (ACA), anti-
phosphatidyl serine (APSA) and anti-endothelial cell (AECA)
activities by cardiolipin liposomes in 18 SLE sera. Inhibition of
less than 10% was taken as not significant
ACA APSA AECA
Serum
No. Patient IgG IgM IgG IgM IgG IgM
1 BR 940 - 926 - <100 -
2 CA 730 740 78 0 490 50 1 42-3
3 BL 89 0 93 0 93 0 86-0 - 18 5
4 BT - 970 - 510 - 49.9
5 RO 930 980 950 930 - 132
6 GA 95-0 - ND ND 10-1 -
7 BO 96-3 - ND ND <10-0 <10-0
8 BE 81-9 925 ND ND - <10.0
9 LO 89-3 97 2 ND ND <10.0 -
10 SC - 74 4 ND ND - <10-0
11 BO - 74 6 ND ND - <10-0
12 PR 93-5 76 1 ND ND <100 -
13 FA 814 77 0 ND ND - <100
14 GE 90-0 85-6 ND ND <10-0 -
15 AL 87-9 - ND ND <100 <10-0
16 SP 82-8 95 2 ND ND 49 3 -
17 MA 745 760 ND ND <100 -
18 MU 78 5 82 7 ND ND 19-0 -
- indicates sera which displayed negative binding to
cardiolipin, phosphatidylserine and endothelial cells for the
corresponding isotypes. ND not done.
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Table 2. Studies with affinity purified anti-cardiolipin anti-
bodies. The endothelial cell binding ofthe affinity purified anti-
cardiolipin antibodies, Cohn fraction II (Cohn F.I1) and
normal human IgM were expressed as ng bound of 125I-labelled
affinity purified goat anti-human IgG or IgM
SERUM AFFINITY PURIFIED
ACA AECA IgG-AECA IgM-AECA
MA + + 8-78 2-76
SP + + 1131 786
MU + + 18-92 7-61
CA + + 5 05 ND
KE + - 6-37 0 81
RE + - 4-65 073
DU + - 075 3-21
COHN F II 3-94
NORMALIgM - 3-12
13
9
C:
0
A
C
o A
C
3- A
250 500 750
Protein concentration (1tg/ml)
Fig. 3. Endothelial cell binding activity of CA affinity purified anti-
cardiolipin preparation at different antibody concentrations. The
binding activity is expressed as ng of anti-IgG bound. The control is
represented by Cohn fraction II at comparable concentrations. O-O
CA affinity purified *-A Cohn fraction II.
Studies with affinity purified anti-cardiolipin antibodies
Finally, affinity purified preparations eluted from cardiolipin
liposomes were tested for their ability to bind to unfixed human
endothelial cells. For this purpose we selected four SLE sera
positive for ACA and AECA, three of which displayed clear
inhibition of the endothelial cell binding after absorption with
cardiolipin liposomes, and three additional sera highly positive
for ACA but negative for AECA. As shown in Table 2,
endothelial cell binding activity was eluted for the four ACA
and AECA positive sera. By contrast, the affinity purified
fractions obtained from the other three sera did not display
endothelial cell binding activity with the exception of the KE
serum.
The affinity purified anti-cardiolipin fractions displayed an
increase in endothelial cell binding by increasing their antibody
concentrations in comparison to the control immunoglobulin
preparations (Fig. 3). Furthermore, to rule out the possibility
that binding occurs via Fc receptors, endothelial cells were
incubated with purified rabbit IgG in order to block the Fc
receptors. The cells were pre-incubated with three different
concentrations of rabbit IgG (50, 500 and 5,000 yg/ml) for one
hour at 37°C, washed three times with HBSS and then tested
with two different affinity purified anti-cardiolipin preparations.
This treatment did not affect the binding of the affinity purified
fractions (affinity purified fraction alone: 4 90 and 7 00 ng of
anti-IgG bound respectively; after cell treatment with 5,000 ug/
ml of rabbit IgG: 5-00 and 6-70 ng bound respectively).
DISCUSSION
The Carreras' hypothesis suggests that anti-phospholipid anti-
bodies (LLAC) can affect endothelial cell functions by reacting
with antigenic determinants present on their surface (Carreras et
al., 1981; Carreras & Vermylen, 1982). In order to investigate
the possible cross-reactivity between anti-phospholipid anti-
bodies and endothelial surfaces, we studied 51 SLE sera for anti-
endothelial cell antibodies and for anti-phospholipid antibodies
identified by the cardiolipin radioimmunoassay. Using a cell
surface radioimmunoassay we confirmed the presence of anti-
endothelial cell antibodies in SLE patients, finding a prevalence
of 39-2% for IgG and of 45-1% for IgM AECA.
Our findings are quite comparable with the data ofShingu &
Hurd (1981) who found 50% of positivities for IgG-AECA in
SLE sera using indirect immunofluorescence on human cultured
endothelial cells. More recently Hashemi, Douglas-Smith &
Izaguirre (1987) using a cellular ELISA assay, demonstrated
that the amount of IgG binding to EC in SLE and normal sera
overlapped considerably although the mean values were higher
in SLE. On the other hand the same authors found a statistically
significant increase in IgM endothelial cell binding activity from
SLE sera. In addition Cines et al. (1984), studying sera from
active SLE patients, showed a significantly increased IgG-
binding activity in 24 out of 27 sera tested.
Little is known in the literature about the association
between AECA and clinical or laboratory parameters in SLE
patients. In this regard we were unable to correlate the presence
of AECA with the clinical and laboratory parameters investi-
gated, including the signs associated with the presence of anti-
phospholipid antibodies (Harris, Gharavi & Hughes, 1985).
Our data contrast with the findings by Le Roux et al. (1986) who
found an association between IgG-AECA, detected by cell
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radioimmunoassay, and LLAC in a smaller series of SLE
patients. This discrepancy could be due to different selection
criteria, because in the Le Roux's series the prevalence ofLLAC
was unusually higher (40%) than in previous reports (6-15%)
(Harris, Gharavi & Hughes, 1985; Shapiro & Thiagarajan, 1982;
Derksen & Kater, 1985; Petri et al., 1987).
Again no correlation was found between positivities for anti-
cardiolipin and for anti-endothelial cell assay, in agreement with
very recent findings by McCarty & Kazava (1988). These data
seem to suggest that the production ofACA and AECA may be
sustained by different pathogenetic mechanisms. However, to
investigate ifanti-phospholipid antibodies can participate in the
whole anti-endothelial cell binding activity, absorption experi-
ments with cardiolipin liposomes were performed in 18 sera
positive both for ACA and AECA. We found that cardiolipin
liposome suspensions, able to inhibit to a great extent the
reactivity against negatively charged phospholipids (cardiolipin
and phosphatidylserine), gave partial inhibition of anti-endo-
thelial cell antibodies in seven samples.
These results suggest that, at least in some SLE sera, only a
part of the whole anti-endothelial cell activity is due to
antibodies which recognize phospholipid structures on the
endothelial cell membranes. On the other hand we showed that
affinity purified anti-cardiolipin preparations from SLE sera
bind endothelial living cells and that the binding does not occur
via the Fc receptors.
It is useful to speculate how some antibody preparations
eluted from cardiolipin liposomes react with endothelial cells,
although no correlation was found between AECA and anti-
cardiolipin levels in SLE sera and AECA was not inhibited by
cardiolipin liposomes in most sera examined.
The lack of correlation between anti-phospholipid and anti-
endothelial cell antibodies, as well as the incomplete inhibition
of anti-endothelial activity by cardiolipin absorption are not
surprising since AECA are probably a heterogeneous antibody
population directed against different antigenic determinants
(Cines et al., 1984; Morales & Stastny, 1977; Simionescu &
Simionescu, 1986) which include membrane phospholipid struc-
tures recognized by the cross-reacting antibodies. In addition,
antibodies eluted from cardiolipin liposomes are polyclonal and
probably contain sub-populations that bind phospholipids with
different affinities, some of which are present on endothelial cell
surfaces. It is possible that polyclonal antibodies eluted from
cardiolipin liposomes have higher concentrations of antibody
sub-populations binding endothelial cell surfaces than is nor-
mally present in patient's serum. This may explain why an
AECA negative serum can give affinity purified anti-cardiolipin
antibodies displaying anti-endothelial cell binding. On the other
hand the polyclonal composition of the affinity purified prep-
arations can also account for the fact that only certain sub-
populations react with endothelial cells. This could be the
reason why the increase in antibody concentration is not
associated with a marked increase in endothelial binding.
Finally, the presence of varying concentrations of sub-
populations of anti-cardiolipin antibodies able to bind endothe-
lial cell surfaces may explain the contradictory results in the
literature with respect to the effects of anti-cardiolipin positive
sera on endothelial cell functions (Izaguirre et al., 1987;
Hasselaar et al., 1987; Schorer, Wickham & Watson, 1988).
Anyway the finding that anti-phospholipid antibodies can react
with surface structures on intact human endothelial cells might
represent the basis to explain one of the pathogenetic mecha-
nisms by which these antibodies affect the coagulation process in
vivo according to the Carreras' hypothesis. This does not
exclude the possibility that other pathogenetic mechanisms can
be mediated by the anti-phospholipid antibodies, as suggested
by their reactivity with negatively charged phospholipids
exposed on the surface of activated platelets (Khamashta et al.,
1988).
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